May 13, 2020
1 min read

Adverum Biotechnologies reports positive interim data from three cohorts of OPTIC phase 1 trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

New interim data for the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy for the treatment of wet age-related macular degeneration showed robust efficacy in each cohort, long-term durability in cohort 1 and the potential for fewer adverse events in cohort 3, according to a press release from Adverum Biotechnologies.

Three cohorts of patients have been treated with a single injection of ADVM-022. The first cohort of six participants was treated with a higher dose of 6 × 1011 vg per eye compared with six participants in the second cohort treated with a lower dose of 2 × 1011 vg per eye. Nine participants in the third cohort were treated with the same lower dose but underwent a 6-week eye drop prophylactic steroid regimen, while cohorts 1 and 2 received a 13-day oral prophylactic steroid regimen.

Interim data showed all six patients in cohort 1 remained free of rescue injections beyond 1 year. Eight of 11 patients who received the lower dose remained free of rescue injections with less follow-up time compared with cohort 1.

Early data from cohort 3 showed the positive potential of the 6-week prophylactic regimen of steroid eye drops, with less inflammation and fewer adverse events when compared with the 13-day prophylactic regimen of oral steroids in cohorts 1 and 2. No patient in cohort 3 required treatment beyond steroid eye drops or had cellular inflammation above grade 1+.

Additionally, in the first five patients with 20 weeks of follow-up in cohort 3, central retinal thickness was reduced by a mean 137.8 µm, and the mean increase in best corrected visual acuity was 6.8 letters.

Cohort 4 is currently being enrolled, with patients receiving the higher dose of ADVM-022 and the same steroid regimen as cohort 3.